We are live on ! Find out more
ALXO icon

ALX Oncology
ALXO

97 hedge funds and large institutions have $273M invested in ALX Oncology in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

16,300% more call options, than puts

Call options by funds: $1.31M | Put options by funds: $8K

57% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 23

20% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 15

1% more funds holding

Funds holding: 96 → 97 (+1)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

2.23% less ownership

Funds ownership: 90.56% → 88.33% (-2.2%)

56% less capital invested

Capital invested by funds: $622M → $273M (-$349M)

Holders
97
Holders Change
+1
Holders Change %
+1.04%
% of All Funds
1.63%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
18
Increased
36
Reduced
23
Closed
15
Calls
$1.31M
Puts
$8K
Net Calls
+$1.3M
Net Calls Change
+$1.22M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$17M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.65M
3
Federated Hermes
Federated Hermes
Pennsylvania
+$4.38M
4
Millennium Management
Millennium Management
New York
+$4.3M
5
BlackRock
BlackRock
New York
+$3.34M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$19.4M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$18.3M
3
Invesco
Invesco
Georgia
-$10.9M
4
UBS AM
UBS AM
Illinois
-$3.84M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$3.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
VP
1
venBio Partners
California
$78.5M – – –
VC
2
Vivo Capital
California
$34.1M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$32.2M +$4.65M +427,260 +12%
LGM
4
Logos Global Management
California
$25.4M +$1.36M +125,000 +4%
BlackRock
5
BlackRock
New York
$13.4M +$3.34M +306,804 +23%
Vanguard Group
6
Vanguard Group
Pennsylvania
$10.7M -$3.82M -350,919 -21%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$9.13M -$18.3M -1,681,725 -60%
RG
8
Redmile Group
California
$6.2M -$61K -5,600 -0.7%
CAM
9
Cormorant Asset Management
Massachusetts
$5.76M – – –
AG
10
Artal Group
Luxembourg
$4.04M – – –
Federated Hermes
11
Federated Hermes
Pennsylvania
$3.69M +$4.38M +402,646 +744%
Morgan Stanley
12
Morgan Stanley
New York
$3.59M +$647K +59,417 +15%
Millennium Management
13
Millennium Management
New York
$3.47M +$4.3M +395,248 +1,161%
PC
14
Pier Capital
Connecticut
$3.22M +$36K +3,302 +0.8%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$3.08M +$652K +59,859 +19%
State Street
16
State Street
Massachusetts
$2.88M -$19.4M -1,777,939 -83%
Deutsche Bank
17
Deutsche Bank
Germany
$2.77M -$20.1K -1,844 -0.5%
SB
18
Samsara BioCapital
California
$2.13M – – –
Goldman Sachs
19
Goldman Sachs
New York
$2M +$362K +33,257 +16%
Two Sigma Investments
20
Two Sigma Investments
New York
$1.98M +$1.06M +97,377 +66%
Renaissance Technologies
21
Renaissance Technologies
New York
$1.84M +$859K +78,883 +53%
Northern Trust
22
Northern Trust
Illinois
$1.62M +$286K +26,292 +15%
ECM
23
ExodusPoint Capital Management
New York
$1.51M +$2.04M +187,258 New
Two Sigma Advisers
24
Two Sigma Advisers
New York
$1.3M +$522K +47,900 +42%
Charles Schwab
25
Charles Schwab
California
$1.23M +$199K +18,234 +14%
1
2 3 4 5

ALXO Hedge Fund Activity: Q2 2022 in Review

97 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q2 2022, worth a combined $273M — down 56% from $622M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ALXO positions and 15 closed out — a net gain of 3 holders — while 36 added to existing stakes and 23 trimmed.

The largest buyer was OrbiMed, adding an estimated $17M. The largest seller was State Street, cutting an estimated $19.4M.

  • 97 institutional investors held ALX Oncology (ALXO) as of Q2 2022, up from 96 in Q1 2022.
  • Funds reported $273M of ALX Oncology stock for Q2 2022, down 56% quarter-over-quarter.
  • 18 funds opened new ALX Oncology positions in Q2 2022 and 15 closed out, a net change of +3 holders.
  • The largest ALX Oncology buyer in Q2 2022 was OrbiMed, an estimated $17M added.
  • The largest ALX Oncology seller in Q2 2022 was State Street, an estimated $19.4M sold.

Based on aggregated 13F filings for Q2 2022.